{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T22:23:03Z","timestamp":1782512583587,"version":"3.54.5"},"reference-count":38,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2002,4,1]],"date-time":"2002-04-01T00:00:00Z","timestamp":1017619200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2002,4]]},"DOI":"10.1053\/ctrv.2002.0261","type":"journal-article","created":{"date-parts":[[2002,10,9]],"date-time":"2002-10-09T20:53:46Z","timestamp":1034196826000},"page":"115-120","source":"Crossref","is-referenced-by-count":19,"title":["The use of temozolomide in recurrent malignant gliomas"],"prefix":"10.1053","volume":"28","author":[{"given":"A.","family":"Gaya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Rees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Greenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Stebbing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/ctrv.2002.0261_RF1","unstructured":"American Cancer Society Cancer Statistics, available at, www.cancer.org"},{"key":"10.1053\/ctrv.2002.0261_RF2","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1136\/jnnp.69.4.464","article-title":"Incidence of brain tumours in two English counties: a population based study","volume":"69","author":"Pobereskin","year":"2000","journal-title":"J Neurol Neurosurg Psychiat"},{"key":"10.1053\/ctrv.2002.0261_RF3","first-page":"14","article-title":"Descriptive epidemiology of primary brain and CNS tumours: results from the central brain tumour registry of the United States, 1990\u20131994","volume":"1","author":"Surawicz","year":"1999","journal-title":"Neurooncology"},{"key":"10.1053\/ctrv.2002.0261_RF4","first-page":"2022","article-title":"Neoplasms of the central nervous system","author":"Levin","year":"1997"},{"key":"10.1053\/ctrv.2002.0261_RF5","doi-asserted-by":"crossref","first-page":"333","DOI":"10.3171\/jns.1978.49.3.0333","article-title":"Evaluation of BCNU and\/or radiotherapy in the treatment of anaplastic gliomas. A co-operative clinical trial","volume":"49","author":"Walker","year":"1978","journal-title":"J Neurosurg"},{"key":"10.1053\/ctrv.2002.0261_RF6","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1056\/NEJM198012043032303","article-title":"Randomised comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery","volume":"303","author":"Walker","year":"1980","journal-title":"N Engl J Med"},{"key":"10.1053\/ctrv.2002.0261_RF7","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1200\/JCO.2001.19.2.509","volume":"19","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1053\/ctrv.2002.0261_RF8","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3322\/canjclin.49.1.8","article-title":"Cancer statistics, 1999","volume":"49","author":"Landis","year":"1999","journal-title":"CA Cancer J Clin"},{"key":"10.1053\/ctrv.2002.0261_RF9","first-page":"59a (abstract 232)","article-title":"CSF levels of temozolomide as a surrogate marker for brain penetration","volume":"20","author":"Stupp","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/ctrv.2002.0261_RF10","doi-asserted-by":"crossref","first-page":"3851","DOI":"10.1200\/JCO.1998.16.12.3851","article-title":"DNA mismatch repair and O6 alkylguanine DNA alkyltransferase analysis and response to temodal in newly diagnosed malignant glioma","volume":"16","author":"Friedman","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1053\/ctrv.2002.0261_RF11","unstructured":"NICE guidance on the use of temozolomide for the treatment of recurrent malignant gliomas. Issued April, 2001, www.nice.org.uk"},{"key":"10.1053\/ctrv.2002.0261_RF12","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1200\/JCO.1999.17.9.2762","article-title":"Multicenter phase ii trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal brain Tumour Group","volume":"17","author":"Yung","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1053\/ctrv.2002.0261_RF13","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/sj.bjc.6600135","article-title":"A rapid and systematic review of the effectiveness of temozolomide for the treatment of recurrent malignant glioma","volume":"86","author":"Dinnes","year":"2002","journal-title":"Br J Cancer"},{"key":"10.1053\/ctrv.2002.0261_RF14","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1054\/bjoc.2000.1316","article-title":"A phase II study of temozolomide vs procarbazine in patients with glioblastoma multiforme at first relapse","volume":"83","author":"Yung","year":"2000","journal-title":"Br J Cancer"},{"key":"10.1053\/ctrv.2002.0261_RF15","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1023\/A:1008382516636","article-title":"Multicentre phase II trial of temozolomide in patients with GBM at first relapse","volume":"12","author":"Brada","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1053\/ctrv.2002.0261_RF16","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/S0959-8049(00)00165-9","article-title":"Health-related quality of life in patients with anaplastic astrocytoma during treatment with temozolomide","volume":"36","author":"Osoba","year":"2000","journal-title":"Eur J Cancer"},{"key":"10.1053\/ctrv.2002.0261_RF17","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1215\/15228517-4-1-39","article-title":"A phase II study of extended low dose temozolomide in recurrent malignant gliomas","volume":"4","author":"Khan","year":"2002","journal-title":"Neuro-oncol"},{"key":"10.1053\/ctrv.2002.0261_RF18","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/BF02796204","article-title":"Phase II study of temozolomide in patients with relapsing high-grade gliomas and poor performance status","volume":"17","author":"Janinis","year":"2000","journal-title":"Med Oncol"},{"key":"10.1053\/ctrv.2002.0261_RF19","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1007\/s002800050691","article-title":"Multicentre CRC phase II trial of temozolomide in recurrent or progressive high grade glioma","volume":"40","author":"Bower","year":"1997","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1053\/ctrv.2002.0261_RF20","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1023\/A:1008336732273","article-title":"Temozolomide as a second line systemic regimen in recurrent high grade glioma: a phase II study","volume":"12","author":"Brandes","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1053\/ctrv.2002.0261_RF21","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S0959-8049(05)80198-4","article-title":"Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours","volume":"29A","author":"O'Reilly","year":"1993","journal-title":"Eur J Cancer"},{"key":"10.1053\/ctrv.2002.0261_RF22","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/bjc.1998.555","article-title":"Phase I study of temozolomide in paediatric patients with advanced cancer. United Kingdom Children's Cancer Study Group","volume":"78","author":"Estlin","year":"1998","journal-title":"Br J Cancer"},{"key":"10.1053\/ctrv.2002.0261_RF23","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.1990.8.7.1277","article-title":"Response criteria for phase II studies of supratentorial malignant glioma","volume":"8","author":"Macdonald","year":"1990","journal-title":"J Clin Oncol"},{"key":"10.1053\/ctrv.2002.0261_RF24","first-page":"10","article-title":"Randomised trial of temozolomide vs procarbazine in glioblastoma multiforme at first relapse","volume":"39","author":"Yung","year":"1998","journal-title":"J Neurooncol"},{"key":"10.1053\/ctrv.2002.0261_RF25","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1002\/1097-0142(19891215)64:12<2420::AID-CNCR2820641204>3.0.CO;2-B","article-title":"Re-evaluation of procarbazine for the treatment of recurrent malignant CNS tumours","volume":"64","author":"Rodriguez","year":"1989","journal-title":"Cancer"},{"key":"10.1053\/ctrv.2002.0261_RF26","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1200\/JCO.2000.18.7.1481","article-title":"Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent GBM","volume":"18","author":"Osoba","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1053\/ctrv.2002.0261_RF27","first-page":"264 (abstract 77)","article-title":"Pre-radiation treatment of newly diagnosed anaplastic astrocytomas and glioblastoma multiforme using temozolomide","volume":"2","author":"Gilbert","year":"2000","journal-title":"Neuro-oncology"},{"key":"10.1053\/ctrv.2002.0261_RF28","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0093-7754(01)90067-3","article-title":"New approaches for temozolomide therapy: use in newly diagnosed gliomas","volume":"28","author":"Stupp","year":"2001","journal-title":"Semin Oncol"},{"key":"10.1053\/ctrv.2002.0261_RF29","first-page":"163a (abstract 632)","article-title":"Promising survival with concomitant and adjuvant temozolomide for newly diagnosed GBM","volume":"19","author":"Stupp","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/ctrv.2002.0261_RF30","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1200\/JCO.20.5.1375","article-title":"Promising survival for patients with newly diagnosed GBM treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide","volume":"20","author":"Stupp","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1053\/ctrv.2002.0261_RF31","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1200\/JCO.1999.17.5.1516","article-title":"Irinotecan therapy in adults with recurrent or progressive malignant glioma","volume":"17","author":"Friedman","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1053\/ctrv.2002.0261_RF32","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/S0093-7754(01)90068-5","article-title":"Temozolomide in combination with other cytotoxic agents","volume":"28","author":"Prados","year":"2001","journal-title":"Semin Oncol"},{"key":"10.1053\/ctrv.2002.0261_RF33","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1200\/JCO.2001.19.9.2449","article-title":"Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy","volume":"19","author":"Chinot","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1053\/ctrv.2002.0261_RF34","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1212\/WNL.54.7.1402","article-title":"Understanding low grade glioma: a decade of progress","volume":"54","author":"Cairncross","year":"2000","journal-title":"Neurology"},{"key":"10.1053\/ctrv.2002.0261_RF35","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1023\/A:1012226718323","article-title":"A phase II trial of temozolomide for patients with recurren or progressive brain metastases","volume":"53","author":"Abrey","year":"2001","journal-title":"J Neurooncol"},{"key":"10.1053\/ctrv.2002.0261_RF36","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S1470-2045(01)00489-2","article-title":"Current and future developments in the use of temozolomide for the treatment of brain tumours","volume":"2","author":"Stupp","year":"2001","journal-title":"Lancet Oncol"},{"key":"10.1053\/ctrv.2002.0261_RF37","article-title":"Phase II study of temozolomide in the treatment of anaplastic astrocytoma at first relapse","author":"Yung","year":"1999","journal-title":"Proc ASCO"},{"key":"10.1053\/ctrv.2002.0261_RF38","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1200\/JCO.20.5.1383","article-title":"Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor marimastat in recurrent and progresive GBM","volume":"20","author":"Groves","year":"2002","journal-title":"J Clin Oncol"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737202902616?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737202902616?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,9]],"date-time":"2019-04-09T07:31:30Z","timestamp":1554795090000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737202902616"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,4]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2002,4]]}},"alternative-id":["S0305737202902616"],"URL":"https:\/\/doi.org\/10.1053\/ctrv.2002.0261","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2002,4]]}}}